Table 1 Patient, disease, and treatment characteristics (N = 65)
Age | Mean (SD) | 65.3 (12.6) | No. (%) | ||
|---|---|---|---|---|---|
Staging | Stage I | 6 (9.2) | |||
Radiation Dose | Median (Range) in Gy | 60 (50–70) | Stage II | 9 (13.8) | |
Stage III | 10 (15.4) | ||||
No. (%) | Stage IV | 39 (60.0) | |||
Sex | Male | 52 (80.0) | Recurrent | 12 (18.5) | |
Female | 13 (20.0) | ||||
Primary Site | Oral cavity/oropharynx | 28 (43.1) | |||
Race | White | 60 (92.3) | Larynx | 8 (12.3) | |
Black | 2 (3.1) | Salivary gland | 7 (10.8) | ||
Asian | 1 (1.5) | Skin | 6 (9.2) | ||
Pacific Islander | 1 (1.5) | Nasopharynx | 5 (7.7) | ||
AI/AN | 1 (1.5) | Nasal cavity/paranasal sinus | 4 (6.2) | ||
Other | 7 (10.8) | ||||
Treatment Type | Adjuvant CCRT | 21 (32.3) | |||
Adjuvant RT | 20 (30.8) | Histology | Squamous cell carcinoma | 51 (78.5) | |
Definitive CCRT | 19 (29.2) | Spindle cell carcinoma | 2 (3.1) | ||
Definitive RT | 5 (7.7) | Papillary thyroid carcinoma | 2 (3.1) | ||
Melanoma | 2 (3.1) | ||||
Chemotherapy | Cisplatin | 25 (38.5) | Merkel cell carcinoma | 2 (3.1) | |
Cetuximab | 8 (12.3) | Adenocarcinoma | 2 (3.1) | ||
Carboplatin | 5 (7.7) | Other | 4 (6.2) | ||
Other | 2 (3.1) |